Spur Therapeutics to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
June 20 2024 - 7:00AM
Spur Therapeutics, formerly Freeline Therapeutics, today announced
that Chief Executive Officer Michael Parini will participate in a
fireside chat at H.C. Wainwright’s 5th Annual Neuro Perspectives
Virtual Conference being held on June 27th, 2024.
The fireside chat will be available starting at 7:00am ET on
Thursday, June 27th for registered attendees of the conference.
Senior management will also participate in one-on-one investor
meetings during the conference.
About Spur TherapeuticsSpur Therapeutics is a
clinical-stage biotechnology company focused on developing
life-changing gene therapies for debilitating chronic conditions.
By optimizing every component of its product candidates, Spur aims
to unlock the true potential of gene therapy to realize outsized
clinical results. Spur is advancing a breakthrough gene therapy
candidate for Gaucher disease and a potential first-in-class gene
therapy candidate for adrenomyeloneuropathy, as well as a research
strategy to move gene therapy into more prevalent diseases,
including forms of Parkinson’s, dementia, and cardiovascular
disease. Expanding our impact, and advancing the practice of
genetic medicine.
Toward life-changing therapies, and brighter futures. Toward
More™
For more information, visit www.spurtherapeutics.com or connect
with Spur on LinkedIn and X.
ContactNaomi
Aokinaomi.aoki@spurtherapeutics.com+ 1 617 283 4298